Edgar Filing: ARCA biopharma, Inc. - Form 4

ARCA biop Form 4	harma, Inc.									
February 17	, 2015									
FORM	14 UNITED STATE	S SECUR	CURITIES AND EXCHANGE COMMISSION							
C 1 1 1				D.C. 20				Number:	3235-0287	
Check this box if no longer			ANGES IN BENEFICIAL OWNERSHIP					Expires:	January 31, 2005	
subject t	0	JF CHAN	GES IN SECUR		CIA	LOW	NERSHIP OF	Estimated	l average	
Section 16. Form 4 or			SLECKTILS					burden ho response	•	
Form 5 obligatio							•	n		
may con <i>See</i> Instr	unue. 20/1	n) of the In	•	•	· ·			511		
1(b).										
(Print or Type	Responses)									
DDIGTOWNICIIAELD			2. Issuer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
	•	Symbol ARCA biopharma, Inc. [ABIO]				(Check all applicable)				
(Last)	(First) (Middle)		f Earliest Ti	ransaction				ek all applicat))C)	
ARCA BIO		10000000000000000000000000000000000000				X_ Director X_ Officer (giv	ve title O)% Owner ther (specify		
CIRCLEPC						below) below) President and CEO				
			ndment, Date Original nth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line)				
WESTMIN	STER, CO 80020	1 neu(moi	itii/Day/Tea)			_X_ Form filed by Form filed by	One Reporting More than One		
(City)	(State) (Zip)	Tabl	a I Non I)orivotivo (Soouri	tion A a	Person quired, Disposed of	or Bonofici	ally Ownod	
1.Title of	2. Transaction Date 2A. De		3.				5. Amount of	6.	7. Nature of	
Security	(Month/Day/Year) Execut		n Date, if Transaction(A) or Disposed of Code (D) Day/Year) (Instr. 8) (Instr. 3, 4 and 5)				Securities	Ownership Form: Direct	Indirect	
(Instr. 3)	any (Month	/Day/Year)				Owned ((D) or	Ownership		
							Following Reported	Indirect (I) (Instr. 4)	(Instr. 4)	
					(A) or		Transaction(s) (Instr. 3 and 4)			
Common				Amount 48,100	(D)	Price				
Stock	02/12/2015		А	<u>(1)</u>	А	\$0	340,725 <u>(2)</u>	D		
									By	
Common Stock							139,082	Ι	Investocor Trust as	
Stock									sole Trustee	
									By NFS	
Common							178,215	Ι	Custodian for Michael	
Stock							170,210		Bristow's	
									IRA	

Edgar Filing: ARCA biopharma, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. 5. Number of Transactio-Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 1 2 ()
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 0.67	02/12/2015	А	25,900	<u>(3)</u>	02/11/2025	Common Stock	25,900	

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
BRISTOW MICHAEL R ARCA BIOPHARMA, INC. 11080 CIRCLEPOINT ROAD, SUITE 140 WESTMINSTER, CO 80020	Х		President and CEO				
Signatures							
/s/Brian I Selby							

Date

/s/ Brian L. Selby, 02/17/2015 Attorney-in-Fact

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2013 Equity Incentive Plan (the "Plan"). The RSUs vest in (1) three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time.

Includes 140,034 previously reported shares issued as restricted stock units under the Plan and 152,591 previously reported shares of (2)common stock held directly.

(3)

8 Ľ S

Edgar Filing: ARCA biopharma, Inc. - Form 4

Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.